PL3908270T3 - Połączenie dekstrometomorfanu i bupropionu do leczenia depresji u pacjentów pochodzenia azjatyckiego - Google Patents

Połączenie dekstrometomorfanu i bupropionu do leczenia depresji u pacjentów pochodzenia azjatyckiego

Info

Publication number
PL3908270T3
PL3908270T3 PL20737928.0T PL20737928T PL3908270T3 PL 3908270 T3 PL3908270 T3 PL 3908270T3 PL 20737928 T PL20737928 T PL 20737928T PL 3908270 T3 PL3908270 T3 PL 3908270T3
Authority
PL
Poland
Prior art keywords
dextromethomorphan
bupropion
depression
treatment
combination
Prior art date
Application number
PL20737928.0T
Other languages
English (en)
Inventor
Herriot TABUTEAU
Original Assignee
Antecip Bioventures Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antecip Bioventures Ii Llc filed Critical Antecip Bioventures Ii Llc
Publication of PL3908270T3 publication Critical patent/PL3908270T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20737928.0T 2019-01-07 2020-01-07 Połączenie dekstrometomorfanu i bupropionu do leczenia depresji u pacjentów pochodzenia azjatyckiego PL3908270T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962789446P 2019-01-07 2019-01-07
US201962789488P 2019-01-07 2019-01-07
US201962789431P 2019-01-07 2019-01-07
US201962789451P 2019-01-07 2019-01-07
PCT/US2020/012612 WO2020146412A1 (en) 2019-01-07 2020-01-07 Combination of dextromethorphan and bupropion for treating depression

Publications (1)

Publication Number Publication Date
PL3908270T3 true PL3908270T3 (pl) 2026-02-16

Family

ID=71521902

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20737928.0T PL3908270T3 (pl) 2019-01-07 2020-01-07 Połączenie dekstrometomorfanu i bupropionu do leczenia depresji u pacjentów pochodzenia azjatyckiego

Country Status (28)

Country Link
EP (2) EP4631571A3 (pl)
JP (1) JP2022516361A (pl)
KR (2) KR20240169131A (pl)
CN (4) CN114712358A (pl)
AU (3) AU2020207261B2 (pl)
BR (1) BR112020025902A2 (pl)
CA (2) CA3126062C (pl)
CL (1) CL2021001810A1 (pl)
CO (1) CO2021008988A2 (pl)
CR (1) CR20210368A (pl)
DK (1) DK3908270T3 (pl)
EC (1) ECSP21051833A (pl)
ES (1) ES3051232T3 (pl)
FI (1) FI3908270T3 (pl)
HR (1) HRP20251402T1 (pl)
IL (1) IL284663A (pl)
LT (1) LT3908270T (pl)
MX (1) MX2021008247A (pl)
MY (1) MY201603A (pl)
NZ (1) NZ777261A (pl)
PE (1) PE20212249A1 (pl)
PL (1) PL3908270T3 (pl)
PT (1) PT3908270T (pl)
RS (1) RS67453B1 (pl)
SG (1) SG11202106392RA (pl)
SI (1) SI3908270T1 (pl)
SM (1) SMT202600055T1 (pl)
WO (1) WO2020146412A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
CN114712358A (zh) * 2019-01-07 2022-07-08 安泰赛普生物风投二代有限责任公司 用于治疗抑郁症的右美沙芬和安非他酮的组合
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
EP4255433A4 (en) * 2020-12-01 2024-05-29 Antecip Bioventures II LLC BUPROPION AND DEXTROMETHORPHAN FOR REDUCING THE RISK OF SUICIDE IN DEPRESSED PATIENTS
AU2022316152A1 (en) * 2021-07-21 2024-02-01 Antecip Bioventures Ii Llc Treatment of depression
EP4384155A4 (en) * 2021-08-09 2025-01-22 Antecip Bioventures II LLC METHODS FOR MAINTAINING REMISSION OF DEPRESSIVE SYMPTOMS
WO2023225511A1 (en) * 2022-05-17 2023-11-23 Antecip Bioventures Ii Llc Treatment of depression
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
WO2025117954A1 (en) * 2023-12-01 2025-06-05 Axsome Therapeutics, Inc. Compounds and combinations thereof for treating depression in patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080097443A (ko) * 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
WO2014057351A1 (en) * 2012-10-11 2014-04-17 Ix Biopharma Ltd Solid dosage form
US20150342946A1 (en) * 2013-01-30 2015-12-03 Pharmorx Therapeutics, Inc. Treatments For Depression And Other Diseases With A Low Dose Agent
US10512643B2 (en) 2013-11-05 2019-12-24 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
CN110279682A (zh) * 2013-11-05 2019-09-27 安泰赛普生物风投二代有限责任公司 包含安非他酮或相关化合物和右美沙芬的组合物和方法
US9402843B2 (en) * 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
JP2017531033A (ja) * 2014-09-14 2017-10-19 アヴェニール ファーマシューティカルズ, インコーポレイテッド 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物
RS61113B1 (sr) * 2014-11-21 2020-12-31 Antecip Bioventures Ii Llc Bupropion za modulaciju nivoa leka dekstrometorfana u plazmi
CN114712358A (zh) * 2019-01-07 2022-07-08 安泰赛普生物风投二代有限责任公司 用于治疗抑郁症的右美沙芬和安非他酮的组合

Also Published As

Publication number Publication date
AU2020207261A1 (en) 2021-07-08
KR20210110654A (ko) 2021-09-08
PT3908270T (pt) 2025-11-12
EP3908270A1 (en) 2021-11-17
CA3126062A1 (en) 2020-07-16
MY201603A (en) 2024-03-05
EP3908270A4 (en) 2022-02-16
CL2021001810A1 (es) 2022-03-04
JP2022516361A (ja) 2022-02-25
ECSP21051833A (es) 2021-11-18
DK3908270T3 (da) 2025-11-17
CN114712358A (zh) 2022-07-08
CN112437659A (zh) 2021-03-02
CO2021008988A2 (es) 2021-09-09
RS67453B1 (sr) 2025-12-31
HRP20251402T1 (hr) 2026-01-02
KR20240169131A (ko) 2024-12-02
CN112437659B (zh) 2022-04-12
WO2020146412A1 (en) 2020-07-16
CA3223187A1 (en) 2020-07-16
AU2020207261B2 (en) 2023-04-13
ES3051232T3 (en) 2025-12-26
FI3908270T3 (fi) 2025-11-24
PE20212249A1 (es) 2021-11-24
EP4631571A3 (en) 2025-11-26
AU2023204348B2 (en) 2025-06-05
LT3908270T (lt) 2025-12-10
CN114712357A (zh) 2022-07-08
AU2023204348A1 (en) 2023-07-27
SG11202106392RA (en) 2021-07-29
BR112020025902A2 (pt) 2021-07-13
AU2025203831A1 (en) 2025-06-19
SMT202600055T1 (it) 2026-03-09
CA3126062C (en) 2024-02-06
NZ777261A (en) 2024-11-29
IL284663A (en) 2021-08-31
MX2021008247A (es) 2021-08-16
SI3908270T1 (sl) 2026-01-30
EP4631571A2 (en) 2025-10-15
EP3908270B1 (en) 2025-08-27
CR20210368A (es) 2021-12-10
CN114712356A (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
PL3908270T3 (pl) Połączenie dekstrometomorfanu i bupropionu do leczenia depresji u pacjentów pochodzenia azjatyckiego
IL289975A (en) Use of cannabidiol in the treatment of Derva syndrome
SI3661954T1 (sl) Muteini interlevkina-21 in postopki zdravljenja
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
ES3058702T3 (en) A vaccine for use in the prophylaxis and/or treatment of a disease
HUE065152T2 (hu) Fluor-fenil-béta-hidroxietilaminok és alkalmazásuk hiperglikémia kezelésében
PL3512517T3 (pl) Stosowanie pridopidyny w leczeniu lęku i depresji
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PL3556377T3 (pl) Dalargin do stosowania w leczeniu ostrych infekcji wirusowych dróg oddechowych
EP3927405A4 (en) ADJUSTABLE EXPIRATORY RELIEF IN RESPIRATORY THERAPY
EP3758633A4 (en) IMPLANTS AND METHODS OF USE AND ASSEMBLY
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL291725A (en) Methods and compositions for treating diabetic retinopathy
IL282836A (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
IL270978B (en) Grape skin for use in the treatment of dysbiosis
EP3634342C0 (de) Silikonpad mit wirkstoffen zur hautpflege und gegen hautalterung
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
MA50358A (fr) Sémaglutide en thérapie médicale
SI3857632T1 (sl) Postopek obdelave katalizatorja iz zlitine platine, obdelanega katalizatorja iz zlitine platine in naprava za izvajanje postopka obdelave katalizatorja iz zlitine platine
EA201390287A1 (ru) Теобромин в комбинации с отхаркивающим или муколитическим средствами для применения в терапии
EP3681410A4 (en) HEART TREATMENT SYSTEM AND METHOD
PL3630112T3 (pl) Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu